Xenetic Biosciences, Inc. XBIO
innovative immuno-oncology technologies addressing difficult to treat cancers. Our proprietary DNase technology is designed to improve
outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps ("NETs"), which are
involved in cancer growth, metastasis and progression, and contribute to immunotherapy, chemotherapy and radiotherapy resistance.
are weblike structures composed of extracellular chromatin coated with histones and other proteins. NETs are expelled by activated neutrophils
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.0M | $2.5M | $2.5M | $1.7M | $1.2M | $436.9K | $17.1K | $0 | $7.6M | $3.0M |
| R&D | $3.1M | $3.3M | $3.5M | $4.8M | $3.2M | $1.7M | $4.9M | $2.9M | $4.1M | $43.7M |
| SG&A | $2.7M | $3.4M | $3.6M | $3.7M | $3.7M | $3.4M | $4.7M | $4.4M | $6.9M | $6.7M |
| Total operating expenses | $5.8M | $6.7M | $7.1M | $8.4M | $6.9M | $14.4M | $12.9M | $7.3M | — | — |
| Operating income | -$2.8M | -$4.2M | -$4.5M | -$6.7M | -$5.7M | -$13.9M | -$12.9M | -$7.3M | -$3.6M | -$47.4M |
| Interest expense | $148.0K | $249.9K | $355.8K | $167.2K | $100.5K | $126.2K | $108.5K | $509 | $1.8K | $729.6K |
| Pre-tax income | -$2.7M | -$4.0M | -$4.1M | -$6.6M | -$5.6M | -$8.0M | -$12.8M | -$7.3M | -$3.6M | -$54.2M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $2.9M | $0 | $0 | $0 | $0 |
| Net income | -$2.7M | -$4.0M | -$4.1M | -$6.6M | -$5.6M | -$10.9M | -$12.8M | -$7.3M | -$3.6M | -$54.2M |
| EPS, basic | -1.58 | -2.57 | -2.71 | -4.61 | -0.55 | — | — | — | — | — |
| EPS, diluted | -1.58 | -2.57 | -2.71 | -4.61 | -0.55 | -1.70 | -6.33 | -9.66 | -0.41 | -7.84 |
| Shares, diluted (wtd. avg.) | $1.7M | $1.5M | $1.5M | $1.4M | $10.3M | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $7.9M | $6.2M | $9.0M | $13.1M | $18.2M | $11.5M | $10.4M | $638.1K | $5.6M | $4.1M |
| Receivables | — | — | — | — | — | — | — | — | $0 | $3.0M |
| Total current assets | $8.0M | $6.6M | $9.6M | $13.7M | $18.7M | $12.4M | $11.1M | $1.2M | $5.9M | $8.3M |
| Property, plant and equipment | — | — | — | $0 | $0 | $0 | $757 | $5.0K | $27.8K | $42.4K |
| Goodwill | — | — | — | — | — | $0 | $9.2M | $3.3M | $3.3M | $3.3M |
| Total assets | $8.4M | $6.9M | $10.6M | $14.7M | $19.8M | $13.2M | $21.5M | $14.4M | $19.2M | $21.0M |
| Accounts payable | $258.1K | $283.6K | $240.8K | $287.4K | $362.5K | $327.4K | $931.1K | $934.1K | $786.8K | $1.0M |
| Total current liabilities | $968.0K | $894.3K | $809.6K | $1.1M | $1.4M | $936.9K | $1.4M | $1.6M | $1.9M | $1.9M |
| Total liabilities | $968.0K | $894.3K | $809.6K | $1.1M | $1.4M | $964.0K | $4.3M | $4.5M | $4.9M | $4.8M |
| Retained earnings | -$199.9M | -$197.2M | -$193.2M | -$189.1M | -$182.5M | -$176.9M | -$166.0M | -$153.2M | -$145.9M | -$142.3M |
| Total equity | $7.4M | $6.0M | $9.8M | $13.6M | $18.4M | $12.2M | $17.2M | $9.9M | $14.3M | $16.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.3M | -$2.8M | -$4.1M | -$4.6M | -$4.7M | -$4.3M | -$6.4M | -$6.5M | $1.5M | -$8.8M |
| Depreciation and amortisation | — | — | — | — | $0 | $757 | $4.2K | $15.8K | $23.8K | $36.4K |
| Stock-based compensation | $64.8K | $171.8K | $283.1K | $511.5K | $410.4K | $468.9K | $806.1K | $1.4M | $1.8M | $1.9M |
| Capital expenditure | — | — | — | — | — | — | — | $0 | $9.3K | $16.8K |
| Investing cash flow | — | — | $0 | -$500.0K | $0 | $0 | $2.0K | $22.5K | -$9.3K | -$16.8K |
| Financing cash flow | $4.0M | $0 | — | $0 | $11.5M | $5.4M | $16.1M | $1.5M | $0 | $12.7M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001683168-26-003207.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |